Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Percheron Therapeutics ( (AU:PER) ) is now available.
Percheron Therapeutics has launched a non-renounceable pro-rata entitlement offer, allowing eligible shareholders to subscribe for two new fully paid ordinary shares for every five shares held as of 20 March 2026, at an issue price of $0.005 per share. Participants will also receive one free-attaching option for every two new shares, with each option exercisable at $0.01 and expiring two years from issue, and the new securities will rank equally with existing shares.
Any securities not taken up under the entitlement offer will be made available through a shortfall offer on the same terms, with eligible shareholders who take up their full entitlement able to apply for additional shares and options subject to board discretion. The offer, which is jointly led by Blue Ocean Equities and Cygnet Capital but not underwritten, is structured to raise additional capital while giving existing shareholders in specified jurisdictions priority access and potential to increase their holdings.
The most recent analyst rating on (AU:PER) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Percheron Therapeutics stock, see the AU:PER Stock Forecast page.
More about Percheron Therapeutics
Percheron Therapeutics Limited is an Australia-based biotechnology company listed on the ASX under the code PER. The company is focused on developing therapeutic products, with its shareholder base primarily located in Australia and selected international markets including New Zealand, Singapore, Hong Kong and the United Kingdom.
Technical Sentiment Signal: Sell
Current Market Cap: A$7.61M
Find detailed analytics on PER stock on TipRanks’ Stock Analysis page.